

What is claimed is:

1. The use of oxcarbazepine for the manufacture of a pharmaceutical composition for the improvement of sleep in human patients suffering from chronic pain.
2. The use according to claim 1 wherein the pain is diabetic neuropathic pain.
3. The use according to claim 1 or 2 wherein oxcarbazepine is administered at a total dose between about 450 mg/day and about 2100 mg/day.
4. The use according to any one of claims 1 to 3 wherein the sleep is improved by decreasing the frequency of being awakened from sleep due to pain.
5. The use according to any one of claims 1 to 3 wherein the sleep is improved by decreasing the delay of getting to sleep due to pain.
6. The use according to any one of claims 1 to 3 wherein the sleep is improved by feeling rested after sleep.
7. A package comprising a pharmaceutical composition comprising as sole active ingredient oxcarbazepine together with instructions for improvement of sleep in human patients suffering from chronic pain.
8. A pharmaceutical composition comprising as sole active ingredient oxcarbazepine for the improvement of sleep in human patients suffering from chronic pain.
9. A method of improving sleep in human patients suffering from chronic pain, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient at a total dose in the range from about 1500 mg/day to about 2100 mg/day.
10. The method of claim 9 wherein a daily dose of from 1650 mg to 1950 mg is administered to the patient.
11. The method of claim 10 wherein the daily dose is about 1800 mg.

12. A method of improving sleep in human patients suffering from chronic pain, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient at a total dose in the range from about 900 mg/day to about 1500 mg/day.
13. The method of claim 12 wherein a daily dose of from 1050 mg/day to 1350 mg is administered to the patient.
14. The method of claim 13 wherein the daily dose is about 1200 mg.
15. A method of improving sleep in human patients suffering from chronic pain which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient at a total dose in the range from about 450 mg/day to about 900 mg/day.
16. The method of claim 15 wherein a daily dose of from 550 mg/day to about 750 mg is administered to the patient.
17. The method of claim 16 wherein the daily dose is about 600 mg.
18. The method according to any one of claims 9, 12 or 15 wherein oxcarbazepine is administering on a twice daily schedule.
19. The method according to any one of claims 1 to 18 wherein the patient is suffering from neuropathic pain.
20. The method according to any one of claims 1 to 19 wherein the patient recruits from the Caucasian population.
21. The method of claim 19 wherein oxcarbazepine is administered in the form of a film-coated tablet.
22. A method of treating pain in a human patient, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient suffering from pain at a total dose in the range from about 1500 mg/day to about 2100 mg/day.

23. The method of claim 22 wherein the daily dose is about 1800 mg.
24. A method of treating pain in a human patient, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient suffering from pain at a total dose in the range from about 900 mg/day to about 1500 mg/day.
25. The method of claim 24 wherein the daily dose is about 1200 mg.
26. A method of treating pain in a human patient, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient suffering from pain at a total dose in the range from about 450 mg/day to about 900 mg/day.
27. The method of claim 26 wherein the daily dose is about 600 mg.
28. The method of claim 22, 24 or 26 wherein the patient is suffering from diabetic neuropathic pain.
29. The method according to any one of claims 22, 24 or 26 wherein the patient recruits from the Caucasian population.
30. The use of oxcarbazepine for the manufacture of a pharmaceutical composition for the treatment of diabetic neuropathic pain.
31. A package comprising a pharmaceutical composition comprising as sole active ingredient oxcarbazepine together with instructions for the treatment of pain.